Research Article

Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response

Author(s):

Inna I. Antoneeva, Tatyana V. Abakumova, Dinara R. Dolgova, Tatyana P. Gening*, Sabina S. Pirmamedova, Dinara F. Myasnikova and Snezhanna O. Gening   Pages 1251 - 1255 ( 5 )

Abstract:

Background: Polychemotherapy in ovarian cancer (OC) is the second major component of treatment. However, treatment with cytostatics is stopped in 25% of cases because of significant side effects. It is shown that concentration of certain cytokines and their balance is largely formed in accordance with a genetic polymorphism. <P></P> Objective: The objective of the study was to evaluate the cytokine status of blood serum of patients with ovarian cancer with different tumor response to neoadjuvant chemotherapy (NACT). <P></P> Method: Patients received 2 courses NACT according to the scheme AP. The levels of IL-1β and IL-1Ra, IL-10, TNF-α in blood serum were determined by solid phase ELISA. For molecular genetic studies we selected polymorphic variants in the promoters of the gene represented in dbS`NP NCBI and SNP500 Cancer databases. <P></P> Results: The sharply declined in patients with ovarian cancer compared with the normal, level of IL-1β correlates with increased levels of IL-1RA. It is found that 75% of patients who had progression of the disease after NACT bear CT genotype of gene IL-1β associated with a low expression of the cytokine, while the TT genotype, providing a high level of the expression of IL-1β gene had met only 25% among patients in this group. At the same time 70% of patients with a complete response are the carriers of the T allele, while a complete response was associated with a higher level of IL-1β than in the progression group. <P></P> Low secretion of TNF-α in all types of tumor response when testing TNF-α G-308A gene polymorphisms was associated with carriage of GA and AA genotypes, which are associated with low production of this cytokine. <P></P> Increased compared to the control IL-10 production in patients with ovarian cancer associated with genotype replacement at position 1082 G/A IL-10 gene, which occured in 10% of patients with a complete response and 25% of patients with tumor progression after NACT. <P></P> Conclusion: All the studied polymorphisms of IL-1β, IL-10 and TNF-α genes in patients with OC are associated with the level of these cytokines and tumor NACT response.

Keywords:

Ovarian cancer, cytokines, gene polymorphism, serum, neoadjuvant, chemotherapy.

Affiliation:

Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017, Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017, Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017, Department of Physiology and Pathophysiology of Ulyanovsk State University Ulyanovsk, 432017, Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017, Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017, Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017

Graphical Abstract:

Read Full-Text article